Use of ADNF polypeptides for treating peripheral neurotoxicity

Details for Australian Patent Application No. 2006227528 (hide)

Owner Ramot at Tel-Aviv University Ltd. Allon Therapeutics, Inc.

Inventors Gozes, Illana; Miller, James

Agent Spruson & Ferguson

Pub. Number AU-B-2006227528

PCT Pub. Number WO2006/099739

Priority 60/664,908 23.03.05 US

Filing date 23 March 2006

Wipo publication date 28 September 2006

Acceptance publication date 26 May 2011

International Classifications

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 45/08 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

C12Q 1/00 (2006.01) Measuring or testing processes involving enzymes or micro-organisms

Event Publications

18 October 2007 PCT application entered the National Phase

  PCT publication WO2006/099739 Priority application(s): WO2006/099739

26 May 2011 Application Accepted

  Published as AU-B-2006227528

22 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227536-Method for isolation of soluble polypeptides

2006227524-Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor